<DOC>
	<DOC>NCT01919996</DOC>
	<brief_summary>This Post-Authorization Safety Study (PASS) is intended to fulfill a regulatory post-marketing requirement to provide data regarding visual abilities in children taking azithromycin (immediate-release formulation) for acute pharyngitis/tonsillitis. The primary objective of the study is to examine the incidence of clinically significant worsening in any of the following ophthalmic exams: best corrected visual acuity (distance), color vision, Amsler grid testing, anterior segment biomicroscopy, and fundus examination, in a group of approximately 30 pediatric patients taking azithromycin oral solution for treatment of an authorized indication of use (pharyngitis/ tonsillitis).</brief_summary>
	<brief_title>PASS Study To Evaluate The Potential Of Zithromax To Cause Ocular Problems In Pediatric Patients</brief_title>
	<detailed_description>Study was terminated prematurely on October 16, 2015 following FDA decision to release Sponsor from post-marketing commitment. No safety and/or efficacy concerns identified.</detailed_description>
	<mesh_term>Pharyngitis</mesh_term>
	<mesh_term>Tonsillitis</mesh_term>
	<criteria>Male or female patient, aged 12 to 17 years. Requires outpatient treatment for acute pharyngitis/tonsillitis infection. Appropriate to treat with oral azithromycin as an alternative to intramuscular penicillin, in the opinion of the investigator. Positive rapid antigen detection test. History of clinically significant eye disorder that would interfere with protocol test procedures. Hypersensitivity to azithromycin, erythromycin, any macrolide, or ketolide antibiotic. Increased risk of QT prolongation. Pregnant or breastfeeding.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Ocular safety</keyword>
	<keyword>azithromycin</keyword>
	<keyword>pharyngitis</keyword>
	<keyword>tonsillitis</keyword>
</DOC>